Crystallographic fragment screening in academic cancer drug discovery
Methods in Enzymology · 2023
DOI: 10.1016/bs.mie.2023.06.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Methods in Enzymology, 2023. Verfasst von Mathew P Martin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Horizons Therapeutic Innovation, Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Translation and Clinical Rese…. Hauptthemen laut MEDLINE: Early Detection of Cancer, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Cancer Research UK, Medical Research Council, Astex Pharmaceuticals.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Horizons Therapeutic Innovation, Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Translation and Clinical Research Institute, Newcastle University, Paul O'Gorman Building, Framling…
Förderung
- Cancer Research UK
- Medical Research Council
- Astex Pharmaceuticals
Zitieren
APA
Martin, M. P., Endicott, J. A., Noble, M. E. M., & Tatum, N. J. (2023). Crystallographic fragment screening in academic cancer drug discovery. Methods in Enzymology. https://doi.org/10.1016/bs.mie.2023.06.021
Vancouver
Martin MP, Endicott JA, Noble MEM, Tatum NJ. Crystallographic fragment screening in academic cancer drug discovery. Methods in Enzymology. 2023. doi:10.1016/bs.mie.2023.06.021
BibTeX
@article{Martin2023,
author = {Martin, Mathew P and Endicott, Jane A and Noble, Martin E M and Tatum, Natalie J},
title = {Crystallographic fragment screening in academic cancer drug discovery},
journal = {Methods in Enzymology},
year = {2023},
doi = {10.1016/bs.mie.2023.06.021}
}
EUVIMED